Metagenomi to Present at 41st Annual J.P. Morgan Healthcare Conference

Metagenomi to Present at 41st Annual J.P. Morgan Healthcare Conference




Metagenomi to Present at 41st Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company powered by the industry-leading portfolio of wholly owned, next-generation gene editing systems, today announced that Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co.

Contacts

Investors:

Simon Harnest

Chief Investment Officer and SVP, Strategy

simon@metagenomi.co
(917) 403-1051

Media:

Ashlye Hodge

Sr. Marketing and Communications Specialist

ashlye@metagenomi.co
(510) 734-4409